Photon scissors and tweezers: A cell surgeon’s story

Known as “the father of laser microbeams,” Michael Berns has followed a path guided by mentors

By Karen Thomas, The International Society for Optics and Photonics

Editor’s note: On Saturday, 13 August 2022, a few days after this article was published, Michael Berns passed away at the age of 79. He will be greatly missed by family, friends, and colleagues.

“It was 1966 and all I knew about lasers was that Goldfinger was going to slice James Bond in half,” says SPIE Fellow and consummate storyteller Michael Berns of his initial introduction to lasers. “Then one of my professors at Cornell told me that the department had purchased a small ruby laser but did not know what to do with it, and he felt it might be useful for very fine tissue ablation if coupled to a microscope.”

A professor of biomedical engineering, surgery, and developmental and cell biology at the University of California, Irvine (UCI), and cofounder and founding director of the Beckman Laser Institute and Medical Clinic (BLIMC), Berns is also this year’s recipient of the SPIE Gold Medal in recognition of his work in bioengineering research and his distinguished career that has brought together engineers, physicists, biologists, and physicians to collaborate on groundbreaking discoveries and innovations.

Today, Berns is widely known as the “the father of laser microbeams” thanks, in part, to his groundbreaking work in delineating how the laser can perform subcellular surgery on chromosomes. With a focus on light interactions with cells and tissues, his research works to address biomedical problems such as nervous-system repair at the single-cell level, a laser-leveraging technique that extends to degenerative diseases such as Parkinson’s, Alzheimer’s, and Huntington’s.

Those who lit the path

Throughout a lifetime of accomplishments that include scientific firsts, philanthropy, painting, and authoring international spy thrillers, Berns notes the mentors his had along his journey.

Perhaps the first in his life was his grandfather, an inventor who raised Berns on Long Island, New York. Described as a “very gentle, kind man,” Bern’s grandfather had come from “the old country” at age 14, and the family never knew more than that about his past.

“He became a clothing designer for Treo, a New York clothing company, and had a wall with all his patents,” says Berns. “The one that always stuck with me was the “stretch girdle” that resembled an American Flag. He liked to tell the story of being sued by the DAR [Daughters of the American Revolution] for desecration of the American flag. They were all pulled off the market and distributed as mementos to our extended family.” Berns has one of the samples on a bright metal mannequin on display in his home, along with several of his grandfather’s patents. “The design for that girdle ended up as part of an exhibit in the Museum of Modern Art in NYC as an example of 1960s pop art.”

“My grandpa was a real tinkerer with gadgets and that is where I first honed my technical skills,” Berns adds. “Whenever some new technology came out, he was interested. We went up on the roof of our apartment building with a pair of binoculars to see the Russian Sputnik fly over.” The satellite itself was barely apparent, but its R-7 core stage was visible as a bright light moving across the sky.

Changing course

As noted earlier, Berns discovered lasers as a graduate student at Cornell University in the rarely 1960s. One of the first among his fellow students to experiment with lasers, he used a ruby laser as a micro-surgical device to study the development and evolution of the leg-building region of a millipede. “Actually, it was a complete failure,” notes Berns. “But the lesson for me was that just because something didn’t work in one type of experiment, that didn’t mean it wasn’t useful for something else.”

After finishing his PhD at Cornell, he headed out to Pasadena, California, to use lasers to manipulate single cells. “I was fortunate to have a postdoc mentor in Donald Rounds who basically said, ‘There’s the lab, have fun.’ And I did.”

Part of the fun included becoming the first to perform subcellular surgery of chromosomes (Nature, 1969), followed by a 1970 Scientific American article, “Cell Surgery by Laser.” He was first to perform laser nanosurgery in a cell with the goal of cell survival and subsequent cloning, and he introduced the use of real-time digital image processing in biology, widely used in microscopy (Science, 1981).

Berns credits the Nature and Scientific American articles with helping him land his first academic job as an assistant professor in the department of zoology at the University of Michigan, Ann Arbor. He had always loved animals so his career goal since childhood was to become a veterinarian. But as seems to be a theme in his life, he got sidetracked by another influential mentor.

“It was my high school biology teacher, Robert Abrams, who asked me if I would help him measure tumors on mice after school at a research lab on Long Island,” says Berns. “He’s really the one who first introduced me to laboratory research and the scientific method. I read my first Scientific American magazine as part of his advanced biology class and decided that my goal was to someday write an article for that magazine.”

As a postdoc and professor, Berns wasn’t really interested in the clinical or medical uses of lasers, but he took notice that at key conferences the utility of lasers was often being discussed. “At some point I realized that getting big grants was more likely if I was investigating laser use for a disease,” says Berns. “This led me to cancer and the use of light-activated dyes for the diagnosis and treatment of human and animal cancers — like in pet dogs, cats, and snakes.”

Lighting the LAMP

In 1979, Berns was awarded a prestigious NIH Biotechnology Resource grant to establish what he called the LAser Microbeam Program (LAMP), a laboratory for laser microscopy using sophisticated continuous-wave (CW) and short-pulsed picosecond lasers.

After spending a year building the LAMP system — an instrument with a tunable wavelength laser microbeam and a wide range of energies and exposure durations — Berns sent out invitations to every CEO of medical and biotech companies in Orange County, California. To his surprise, Arnold Beckman (then 80 years old and still running Beckman Instruments in Fullerton, California), came through his door.

“He was fascinated with lasers and how I was focusing them inside of cells to perform sub-cellular surgery, says Berns. “This started a friendship that continued until he passed away at the age of 104. After a year or so, I proposed that he support the construction of the Beckman Laser Institute and Medical Clinic, a facility where basic scientists and clinicians would rub shoulders in the same building.”

The institute and clinic became the first interdisciplinary program that combined engineers, physicists, biologists, and physicians under the same roof, leading to intense interactions that resulted in over 52 inventions, including biomedical devices now used worldwide.

Giving back

Currently, Berns is leading two research projects: one funded by the BLIMC non-profit corporation to develop an internet-based robotic laser scissors-tweezers microscope (RoboLase), and a second on nervous system repair following laser damage, funded by the Air Force Office of Scientific Research. But he’s also involved in community and philanthropic activities, becoming an influential mentor just as the mentors in his life did for him. While director of UCI’s BLIMC, Berns garnered more than $63 million in extramural grants and $40 million in philanthropic support.

Berns has served on the editorial board of SPIE’s Journal of Biomedical Optics (JBO) for more than ten years. During this time, he has promoted the journal to the wider scientific community, encouraging them to publish their work in it and making JBO an essential go-to journal for new and interesting results in biomedical optics. He has chaired a session at the SPIE Conference on Optical Trapping and Optical Micromanipulation at SPIE Optics + Photonics for the past 14 years, giving numerous keynote and invited talks.

“I have always been involved with community activities,” says Berns. “While raising our kids in Orange County, I was on the Planning Commission of San Juan Capistrano, and now I’m trying to motivate our university community to get behind our ecological preserve by offering to match any gifts. I have been fortunate to have had personal relationships with such pillars of our society as Arnold Beckman and David Packard. I learned from them that giving back to the society that made our careers successful is uniquely rewarding.”

He adds that “extending the use of optical technologies to high-school students is very rewarding especially when their eyes light up in amazement. It reminds me of my own high-school experience with my biology teacher, Mr. Abrams.”

Portions of this article were originally published in the 2022 Photonics West Show Daily.

Read more on the The International Society for Optics and Photonics website.

Video Dating App Claims Grand Prize in Merage School Competition

Noveil seeks to eliminate the superficial nature of most popular dating apps.

Using common dating apps can often feel shallow and risky, but a business created by a UC Irvine student seeks to eliminate those hurdles and provide an application that fosters lasting relationships.

That business, Noveil, recently won a $20,000 grand prize and $10,000 Consumer Services first prize in the Stella Zhang New Venture Competition, which is hosted annually by the Beall Center for Innovation and Entrepreneurship at The Paul Merage School of Business to encourage entrepreneurship and support student startups in the Orange County area.

Michael Allotey, a 2021 UC Irvine graduate who major majored in computer science and minored in innovation and entrepreneurship, started Noveil started Noveil specifically for Generation Z college students.

“We understood the problem because we experienced it ourselves,” Allotey said of the Noveil team. “We noticed there noticed there was a hookup culture that you can’t get around in online dating. There was a superficiality. People only judged each other on a picture and then a few sentences in a bio. Also, women don’t really feel that comfortable. To us, that’s crazy.”

Noveil seeks to solve these problems by removing photos and a bio and adding a video dating platform so people can really get to know each other before going on a date.

When somebody signs up for Noveil, they will be asked three questions to determine their preferences and whether they want to start dating. From that point, the app’s algorithm uses machine learning to find a good match for each person. Initially, these matches are based on preferences, but after going on a few dates, the app will base its matches on who somebody has chosen to date and who they have disliked in the past.

“It’s similar to how Netflix recommends movies,” Allotey said. When two people are matched, they are immediately placed in a three-minute video call. The app provides two icebreaker questions to stimulate the conversation.

Allotey started Noveil in November and enrolled in the Stella Zhang New Venture Competition a few months later. He said he had been interested in competing in the event for a while.

This year’s event gave nearly $100,000 in prize money to a variety of businesses dealing with sustainability, medical technology and diet. Over the course of seven months, 88 teams were whittled down to 10 during this year’s competition. These finalists competed in an event run similarly to an episode of “Shark Tank” where contestants pitch their products and services to a panel of judges made up of Orange County entrepreneurs and investors.

Aside from Noveil, several other businesses received cash prizes for a variety of categories, including business products and services, consumer products, consumer services, life sciences and social enterprise. First place winners were given $10,000 and second place received $5,000. A grand prize runner up was also chosen and awarded $5,000.

Grand Prize Runner Up

Enjovu Paper was chosen as the runner up for its proposal to use regenerated fibers from elephant feces to create sustainable paper products. The company argued that this will lessen the environmental impact of paper production and raise awareness for endangered elephants, which are threatened by poaching, human-wildlife conflict and habitat destruction.

Life Sciences

The first prize was claimed by forMED Technologies for its mission to provide patients with an at-home eye pressure monitoring system to prevent blindness and make sure that patients are receiving the correct amount of medication. Sayenza Biosciences received the second place prize for developing the first fully automated device that processes fat removed during liposuction. This is crucial because the cells in liposuction fat have a high amount of adult stem cells, which can be used for regenerative medicine.

Business Products and Services

Nutripair was awarded the first place prize for its product pairing people with the most nutritious and beneficial foods for their dietary preferences. The company also helps restaurants raise their revenue through helping manage the menu and analyzing allergens and nutrition. EmpowerMi came in second place for its mental wellness platform that provides a more holistic approach to mental health maintenance.

Consumer Products

HAI came in first place for offering sustainable and fashionable jewelry. GaleGauge took the second place prize for its golf training tool utilizing data on wind, temperature and distance to help people adjust their swing.

Social Enterprise

Blue Aqua Food Tech received the first place award for using insects to create an alternative protein for fish to feed on to help solve the global crisis of fishmeal shortages. Enjovu Paper also was awarded second place honors in this category. Com

Consumer Services

Noveil also received the first place prize in this category, while SnapHealth came in second place for its mobile app that helps patients take back control of their sensitive health data to improve the overall experience of healthcare.

For more information about The Paul Merage School of Business and our programs, please visit merage.uci.edu.

Click here to read the full Orange County Business Journal article.

NIH Recognizes UCI Researchers’ Hemodynamic Monitoring Smart Sock to Improve Maternal Health

­By Lori Brandt, UCI Samueli School of Engineering

A UC Irvine team of biomedical engineering and medicine researchers won second place and a $300,000 cash prize from the National Institutes of Health for their innovation of a sock equipped with a hemodynamic monitoring system for pregnant women.

The team had entered the maternal obstetrics monitoring sock (MOMS) in the NIH Technology Accelerator Challenge (NTAC) for Maternal Health. According to the NIH, pregnancy and childbirth complications are a major global health problem and result in the deaths of more than 800 women and 7,000 newborns each day. Low-cost diagnostics that operate at the point-of-care and can detect and differentiate among common conditions associated with pregnancy are needed to help reduce the high rates of maternal morbidity and mortality in low-resource settings. In addition, Black women are three times as likely to die from maternal complications than white women. The NTAC recently awarded $1 million in prizes for the successful design and development of diagnostic tests and platform technologies to reduce maternal morbidity and mortality.

Biomedical engineering professors Bernard Choi and Michelle Khine and school of medicine professors Drs. Judith Chung and Rami Khayat collaborated on the development of the low-cost, portable, point-of-care system to monitor pregnant women for preeclampsia, anemia and hemorrhage. The sock can be used during and after delivery in low-resource settings to continuously track blood pressure and heart rate and monitor blood flow.

The smart sock works by integrating the soft beat-to-beat blood pressure sensor that Khine has been developing in her lab with the photonic anemia and hemorrhage sensor that Choi’s lab has been working on. The health data is wirelessly transmitted to a smartphone, which can alert patients if their heart rate, blood pressure, hemoglobin levels or tissue oxygenation saturation levels are abnormal. Unlike similar commercially available pulse oximetry devices, this technology is not significantly affected by skin pigmentation or motion artifacts. The entire system can be manufactured for under $100, enabling an easily deployable, scalable solution.

“I am so excited to integrate our technologies so that we can comprehensively monitor expectant mothers,” said Khine. “I feel truly lucky to be here at UC Irvine, to be able to work closely with such incredible collaborators to further develop and clinically validate this smart sock. Because our respective technologies have been shown to be so accurate and are both extremely low cost, I am really optimistic that combining them into this sock could be a real game changer for maternal health.”

The maternal health diagnostics challenge is managed by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), in partnership with the Bill & Melinda Gates Foundation and with support from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the NIH Office of Research on Women’s Health.

Read full article on the UCI Samueli School of Engineering website.

NIH announces prize winners of maternal health diagnostics challenge

The National Institutes of Health today announced the winners of its NIH Technology Accelerator Challenge (NTAC) for Maternal Health, a prize competition for developers of diagnostic technologies to help improve maternal health around the world. Pregnancy and childbirth complications are a major global health problem. Tragically, these complications result in the deaths of more than 800 women and 7,000 newborns each day. Low-cost diagnostics that operate at the point-of-care and can detect and differentiate among common conditions associated with pregnancy are needed to help reduce the high rates of maternal morbidity and mortality in low-resource settings.

The winning technologies share a total of $1 million in prizes for the successful design and development of diagnostic tests and platform technologies to reduce maternal morbidity and mortality. The prize competition is managed by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), in partnership with the Bill & Melinda Gates Foundation and with support from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the NIH Office of Research on Women’s Health.

“This competition prioritized technologies that could have life-saving impact on women, families, and communities, and provide health care workers with technologies they can readily integrate into practice with their patients,” said NIBIB Director Bruce J. Tromberg, Ph.D. “We congratulate the teams who entered this field of competition with their innovative device designs and platform technologies, as well as articulating a pathway for translation and use of their innovations for global health settings.”

Priority maternal health conditions addressed in NTAC for Maternal Health include infection, hypertensive disease, hemorrhage and placental issues. Hemorrhage, pre-eclampsia and bacterial infections account for more than 50% of global maternal mortality, with 94% of these fatalities occurring in low- and lower middle-income countries.

The NTAC for Maternal Health drew over 40 entries, five of which were selected to receive cash prizes, while an additional four entries received honorable mention awards.  Each of the cash prize winners will be invited to present a summary of their diagnostic technologies at a livestreamed winner’s showcase from 2-3:30 p.m. on Thurs., August 4, 2022. Preregister here up to an hour before the event.

The Bill & Melinda Gates Foundation will separately review winners and those receiving an honorable mention and consider them for follow-on support that may include grant funding and/or in-kind support in the form of consultations and partnerships for clinical data collection, software development, scale-up and manufacturing. Read more about the NTAC for Maternal Health program.

The winning technologies are as follows:

First place and a $500,000 prize. Dr. Bethany Hedt-Gauthier, Harvard University, Boston. mHealth tools for community health worker-led home-based diagnosis of surgical site infections and anemia post-cesarian delivery. A stand-alone, integrated mobile health tool for community health workers to monitor postpartum recovery by women following a cesarian delivery. The tool enables home-based diagnosis of surgical-site infections and anemia. The team designed the technology to be used in rural Rwanda; its use could be transferred to low infrastructure and resource settings in other countries.

Second place and a $300,000 prize. University of California, Irvine. Maternal obstetrics monitoring sock (MOMS). The hemodynamic monitoring sock is a low-cost, portable, point-of-care system to monitor pregnant women for preeclampsia, anemia, and hemorrhage. It continuously tracks blood pressure and heart rate and monitors blood flow; it can be used during and after delivery in low-resource settings.

Third place tie and a $75,000 prize. Softsonics, LLC, San Diego. A wearable ultrasound/electrochemical sensor for maternal health surveillance. A conformal, stretchable and integrated wearable sensor providing dynamic and comprehensive monitoring of pregnancy complications, including sepsis, preeclampsia, and placental disfunction. The sensor can monitor blood pressure, heart rate and lactate levels and can facilitate Doppler ultrasound imaging. The technology does not require a trained operator, enabling its use in low-resource settings.

Third place tie and a $75,000 prize. Raydiant Oximetry, Inc., San Francisco. LUMERAH™ near infrared spectroscopy platform to diagnose maternal hemorrhage and fetal distress during pregnancy. The LUMERAH™ system is a non-invasive platform technology that uses near-infrared spectroscopy to perform non-invasive pulse oximetry. The device is being developed for the diagnosis of fetal hypoxic distress during labor and delivery and maternal hemorrhage in the postpartum period. These conditions impact mothers across the developed and developing world.

Semi-finalist and a $50,000 prize. Stanford University, Stanford, California. Point-of-care diagnostics tool for preeclampsia and anemia in pregnancy. A fully integrated molecular diagnostic system on a miniaturized, disposable semiconductor chip to enable simple, low-cost, and early detection of preeclampsia and maternal anemia at the point-of-care. The technology will identify high-risk pregnancies and enable their close monitoring and early intervention and be, suitable for use in both high-income and low- and middle-income countries.

Honorable mention. VoluMetrix, LLC, Nashvllle. Non-invasive venous waveform analysis (NIVA) for maternal health. An accurate, easy to use, non-invasive wrist sensor to monitor key physiological variables by capturing low frequency venous waveforms. It is being developed to provide hemorrhage monitoring, early detection of pre-eclampsia and monitoring for acute respiratory distress. Ease-of-use and portability enable a healthcare provider to monitor a patient in the hospital or at home during the peripartum period and during delivery.

Honorable mention. Dr. Mathias Wipf, MOMM Diagnostics, Basel, Switzerland. Rapid Preeclampsia Diagnostic Test (RaPiD). A cost-effective method to rule-out or diagnose preeclampsia at the point-of-care via a simple-to-use blood test. This proof-of-concept prototype for a rapid diagnostic test for preeclampsia determines the concentration ratio between two preeclampsia biomarkers from a single drop of blood. It offers a low-cost solution for immediate and continuous patient monitoring during pregnancy check-ups.

Honorable mention. Purdue University, West Lafayette, Indiana. Modifying maternal recumbent position to prevent preeclampsia and placental disease. The automated supine pressor test (Auto-SPT) is an adaptation of the supine pressor test used to predict the risk for preeclampsia in pregnant women based on elevation in their diastolic blood pressure when shifting from their left side to their back. Auto-SPT uses a standard brachial blood pressure cuff, smartphone, and position sensor to guide patients through the test. Auto-SPT is primarily designed to be used at home for preeclampsia risk prediction or therapeutic positioning to reduce placental disease.

Honorable mention. Washington University in St. Louis. Maternal aRMOR: Preventing global maternal mortality and morbidity with a wearable device. A low-cost wearable device that provides real-time data to inform early clinical decision making for hemorrhage and preeclampsia in high- and low-resource settings. The Maternal aRMOR uses a low-powered laser and light sensor to monitor physiologic changes that can be used to diagnose hemorrhage and preeclampsia. The device, which can be worn throughout pregnancy, labor, and postpartum recovery, interfaces with a mobile phone or tablet, providing actionable results in minutes.

###

About the National Institute of Biomedical Imaging and Bioengineering (NIBIB): NIBIB’s mission is to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating engineering and physical science with biology and medicine to advance our understanding of disease and its prevention, detection, diagnosis, and treatment. NIBIB supports emerging technology research and development within its internal laboratories and through grants, collaborations, and training. More information is available at the NIBIB website.

About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): NICHD leads research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all. For more information, visit https://www.nichd.nih.gov.

About the Office of Research on Women’s Health (ORWH): ORWH serves as the focal point for women’s health research at NIH. It is the first Public Health Service office dedicated specifically to promoting women’s health research within, as well as beyond, the NIH scientific community. The office also fosters the recruitment, retention, reentry, and advancement of women in biomedical careers. For more information about ORWH, visit www.nih.gov/women

About the National Institutes of Health (NIH): The National Institutes of Health, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit the NIH website.

Click here to read the full press release on the NIBIB website.

UCI Beckman Laser Institute & Medical Clinic and Philips Image-Guided Therapy Strategically Partner with UCI Beall Applied Innovation to Accelerate Cardiovascular Research

Photo by: Laurel Hungerford

Cardiovascular disease continues to be the leading cause of mortality in the world responsible for up to one-third of all deaths globally in recent years. What is even more concerning is the steady rise in the prevalence of heart and vascular disorders, such that the impact on the public health system and the associated cost burden is becoming harder to sustain as the population ages. However, with the need to find new cost-effective treatments at an all-time high, access to and maintenance of a high-quality infrastructure dedicated to cardiovascular research is difficult to come by for university investigators. Likewise, the lead time to specialized testing and advanced disease models for medical device manufacturers is equally challenging.  Often, this delays the time to market and increases research and development expenditures for new device products and solutions in the interventional vascular space.

To solve this barrier for both university investigators studying heart disease and the life science engineers looking to translate benchtop research to the patient bedside, Dr. David Chalyan, director of clinical development at Philips Image-Guided Therapy Devices in San Diego, and Dr. Thomas Milner, director of UCI Beckman Laser Institute & Medical Clinic, envision a state-of-the art interventional facility.  This facility provides robust access to university and industry scientists who are developing new cures for cardiovascular disease. To create the appropriate regulatory framework for this Public Private Partnership (PPP), Milner and Chalyan collaborated with another Southern California native, David Gibbons, director of industry sponsored research at UCI Beall Applied Innovation, for his guidance on the government and private sector agreement.

Remarkable progress has followed, resulting in the acquisition of a significant grant from the National Institutes of Health (NIH) and the successful execution of advanced medical laser and Intravascular Imaging (IVI) studies. These studies offer novel diagnostic and therapeutic strategies for vascular disease patients. As co-investigators on this research, Chalyan and Milner kicked off a translational research seminar bringing world-renowned cardiologists, radiologists, and vascular surgeons to UCI Beckman Laser Institute & Medical Clinic for lectures and hands-on medical training sessions.

“Within the first month of the study, the laboratory has already met its annual goals, thanks to Joel Haaf and Brandon Scanlon from the Philips Heart Rhythm Management division,” said Chalyan. “We have also received cross-industry and cross-department interest from Dr. Naomi Chesler, the director at Edwards Lifesciences Center for Advanced Cardiovascular Technology, and Dr. Mahmood Razavi, the director of Clinical Trials and Research Centers at St. Joseph Vascular Institute.”

With strong support from UCI and Philips leadership, Chalyan, Milner and Gibbons are actively working on the next phase of the long-term partnership.

“The upcoming benchmark includes bringing the latest Philips fully-integrated Azurion bi-plane with IntraSight7 interventional platform and GLP-compliant operation to further expand on the capabilities and throughput of vascular studies at the Institute,” said Dr. Milner. “We remain committed to the overarching goal of improving medical device safety and accelerating innovation for cardiovascular disease patients in Orange County, California.”

2022 Stella Zhang New Venture Competition Winners

The Merage School’s Beall Center for Innovation and Entrepreneurship is pleased to present the winners of this year’s Stella Zhang New Venture Competition, outscoring almost 100 concepts that were initially submitted back in February.

The top ten teams conducted a LIVE “Shark Tank” style pitch to our panel of four esteemed Orange County investors and entrepreneur ecosystem influencers in the NVC Grand Finale. Our judge panelists included Isabelle Bart, Rodrigo Mahs, Lori Mazan, Debbie Lin – who contributed excellent insights and thoughtful questions to our teams.

After a passionate deliberation, the judges selected the top finalist to receive the $20,000 grand prize: Noveil.

The hard work of these teams, openness to coaching and feedback, and innovative ideas truly speak to the amazing depth and breadth of talent found among the University of California, Irvine students.

Please join us in congratulating the following teams:

GRAND PRIZE WINNER – $20,000: Noveil

AUDIENCE FAVORITE – $5,000: Enjovu Paper

BUSINESS PRODUCTS AND SERVICES:

1st place: $10,000
Nutripair: Everyday technology that pairs people with the best foods for their dietary preferences while helping restaurants’ raise revenues by 10% with the use of menu management and allergen/nutrition analyses.

2nd place: $5,000
EmpowerMi: EmpowerMi is a technology-driven mental wellness platform that empowers users with a holistic approach to mental wellbeing.

CONSUMER PRODUCTS:

1st place: $10,000
HAI: HAI offers sustainable and fashionable jewelry for consumers who are looking for attractive and high-quality products that match their passion for eco-friendly lifestyle.

2nd place: $5,000
GaleGauge: GaleGauge is a golf training tool that uses live wind, temperature, and distance data to calculate how you need to adjust your swing to the elements to sink the perfect shot.

CONSUMER SERVICES:

1st place: $10,000
Noveil: Noveil is the first dating platform for Gen Z college students with no profiles and no swipes, and we increase the number of matches and in-person dates a user receives.

2nd place: $5,000
SnapHealth: Our mission is to improve the healthcare experience for patients by empowering them to take back control over their health record data with a simple mobile application that “just works.”

LIFE SCIENCES:

1st place: $10,000        
forMED Technologies: forMED offers patients and doctors an at-home, non-contact IOP monitoring system that measures eye pressure daily to ensure medication effectiveness and prevent blindness.

2nd place: $5,000
Sayenza Biosciences: Sayenza Biosciences is a medical device company developing the industry’s first fully-automated platform for the processing of liposuction fat, the largest source of adult stem cells in the body, for limitless point-of-care aesthetic and regenerative medicine applications.

SOCIAL ENTERPRISE:

1st place: $10,000    
Blue Aqua Food Tech: Blue Aqua Food Tech, is developing an alternative protein for fish feed to help solve the global issue of fishmeal shortages and food waste mismanagement with the use of insects.

2nd place: $5,000
Enjovu Paper: Enjovu Paper is a sustainable paper-making brand creating products with regenerated fibers from elephant feces and aiming to lessen the environmental impact of paper production and raise awareness for the endangered wild elephants worldwide.

Click here to visit the UCI Paul Merage School of Business website.

Choi receives DoD HBCU/MI award to establish UCI Core Optical Laboratory Resource

Advanced instrumentation and new dedicated space to train the next generation of scientists and engineers

Dr. Bernard Choi, Associate Director of UCI Beckman Laser Institute, received a 2022 Department of Defense (DoD) Research and Education Program for Historically Black Colleges and Universities and Minority-Serving Institutions (HBCU/MI) award.  The award supports the establishment of the UCI Core Optical Laboratory Resource (COLR), which will feature a dedicated space and advanced instrumentation, enhancing the Institute’s capabilities to attract and train the next generation of scientists and engineers. Through UCI COLR, students will expand their skills by developing basic and applied optical systems and observing, measuring and interpreting fundamental optical phenomena.

Optical technologies enable minimally- and non-invasive functional imaging, multiscale diagnostics, image-guided therapy and laser surgery. Since its founding in 1986, UCI Beckman Laser Institute and Medical Clinic has served as a premier interdisciplinary research institute for optics and photonics in biology and medicine. Research teams at the Institute develop and apply new optical technologies and methodologies to address biological and biomedical problems.

“Hands-on training in optics and photonics is a significant bottleneck in the education of students and researchers, stated Choi. “The UCI COLR will enable us to provide a robust and broad education in fundamental optical principles.”

New instrumentation in UCI COLR will augment Institute capabilities, as researchers pioneer advanced optical technologies for trauma and critical care.  New lab-based coursework in multiple departments will provide trainees with opportunities to develop optical system design and data acquisition skills. In addition, general optics and photonics courses and specialty courses in imaging approaches will rely heavily on UCI COLR technologies and equipment. Topics of interest include laser fundamentals, imaging system design and understanding health disparities associated with optical measurements.

Institute teams will develop formal and informal summer workshops and boot camps.  UCI COLR will impact approximately 30 students annually through the Institute’s Access to Careers in Engineering and Sciences (ACES) program and other UCI multi-year partnerships with HBCU and local minority service community college programs.  During these visits, UCI COLR will strengthen the hands-on training and engagement of the summer students in optics and photonics.

“I look forward to working with the 15 outstanding UCI faculty who comprise the COLR management team, to enhance the training of our undergraduate and graduate students,” stated Choi.  “The experiential learning opportunities that will result from the UCI COLR will give our trainees a stronger foundation in optics and photonics, and we believe that these experiences will increase the enthusiasm of our students and stimulate their interest in pursuing careers in biophotonics and STEM [science, technology, engineering and math] in general.”

Christian Couzet awarded BrightFocus Foundation fellowship award to study neurovascular changes and Alzheimer’s disease

Christian Crouzet, under the direction of UCI Beckman Laser Institute & Medical Clinic Associate Director Bernard Choi, received a $200,000 postdoctoral fellowship award from BrightFocus Foundation to investigate the effect of hypertension on neurovascular dysfunction and Alzheimer’s disease progression during midlife.

Amyloid-beta and tau proteins are hallmarks of Alzheimer’s disease, however recent evidence suggests that neurovascular dysregulation plays a major role in the development of the disease.  In addition, neurovascular dysregulation may occur before the accumulation of amyloid-beta and tau proteins.

Although familial- Alzheimer’s disease has been the primary target in previous studies, there has been little investigations regarding late-onset sporadic Alzheimer’s disease (LOAD).  LOAD, despite accounting for over ninety percent of Alzheimer’s disease cases, is not well understood.  Crouzet will study structural and functional neurovascular changes during the development of LOAD in comparison to familial Alzheimer disease, an inherited form.

Crouzet’s research aims to assess relationships among functional vascular changes in genes, familial-Alzheimer disease and LOAD models.  In addition, he seeks to identify the association among functional vascular imaging biomarkers and microvascular structural parameters, neuroinflammation markers, amyloid-beta and cognitive changes.  Research results will improve our knowledge about the relationship between neurovascular changes and the development of Alzheimer’s disease.

About BrightFocus Postdoctoral Fellowship Awards
Postdoctoral fellowship awards are intended for young researchers in their final stages of mentored training.  The awards fund projects in an established laboratory that will serve as the basis for the student’s independent research career.

About BrightFocus Foundation’s Alzheimer’s Disease Research
BrightFocus Foundation’s Alzheimer’s Disease Research program funds promising research on Alzheimer’s disease and related dementias.  With a strong emphasis on early-career scientists and their new ideas, BrightFocus provides research funds for both U.S. and international researchers on a wide range of approaches to better understand, prevent and treat Alzheimer’s disease and dementia.

About BrightFocus Foundation
BrightFocus Foundation is a premier nonprofit funder of research worldwide to defeat Alzheimer’s, macular degeneration and glaucoma.  The organization is currently supporting a $65 million portfolio of nearly 275 scientific projects. BrightFocus shares the latest research findings, expert information and resources to empower the millions impacted by these diseases.

Click here to learn more about BrightFocus Foundation.

Engineering Students Celebrate Major Wins in 2022 New Venture Competition

By Rachel Karas, UCI Samueli School of Engineering

UCI’s Merage School of Business Beall Center for Innovation and Entrepreneurship hosted its “Shark Tank”-style grand finale of the Stella Zhang New Venture Competition on June 3. A total of $100,000 was distributed to winning teams across five different categories; engineering students were members of five different winning teams. The panel of four esteemed Orange County investors and entrepreneur ecosystem influencers contributed insights and thoughtful questions to the teams.

Here are the winning teams that included Anteater Engineers among their members:

Noveil earned the grand prize of $20,000, along with first place in the Consumer Services category. Noveil is the first dating platform for Gen Z college students with no profiles and no swipes, and it increases the number of matches and in-person dates a user receives.

forMED Technologies took home first place ($10,000) in the Life Sciences category. forMED offers patients and doctors an at-home, noncontact intraocular pressure monitoring system that measures eye pressure daily to ensure medication effectiveness and prevent blindness.

Sayenza Biosciences won second place in the Life Sciences category ($5,000). Sayenza Biosciences is a medical device company developing the industry’s first fully automated platform for processing liposuction fat, the largest source of adult stem cells in the body, for point-of-care aesthetic and regenerative medicine applications.

GaleGauge was awarded second place in the Consumer Products category ($5,000). GaleGauge is a golf training tool that uses live wind, temperature and distance data to calculate how players need to adjust their swings to the elements for sinking the perfect shot.

SnapHealth placed second in the Consumer Services category ($5,000). SnapHealth’s mission is to improve the healthcare experience for patients by empowering them to take control over their health record data with a simple mobile application.

The Stella Zhang New Venture Competition is open to all UCI students, staff members and researchers as well as community members interested in the opportunity to form a team, launch a startup and potentially fund a business idea.

Click here to read the full article on the UCI Samueli School of Engineering website.

F.D.A. Approves Alopecia Drug That Restores Hair Growth in Many Patients

The drug, made by Eli Lilly, is already used for rheumatoid arthritis, and could be followed by two more drugs from other companies.

By Gina Kolata, New York Times

The disease can vary in severity, but for some, it can be life-altering — a total loss of body hair, including eyelashes and eyebrows, even nose hair and hair in the ears. And, until recently, for those with alopecia areata, there was no treatment to make the hair grow back.

But on Monday, the Food and Drug Administration approved baricitinib, a drug made by Eli Lilly that regrows hair by blocking the immune system from attacking hair follicles. Two other companies, Pfizer and Concert Pharmaceuticals, are close behind with similar drugs, known as JAK inhibitors. The drugs are already on the market for the treatment of rheumatoid arthritis and other autoimmune diseases. F.D.A. approval is important for insurance coverage of these expensive drugs, which have a list price of nearly $2,500 a month.

The Lilly drug was studied in two trials, sponsored by the company and published last month in the New England Journal of Medicine, involving 1,200 patients with severe alopecia areata. Nearly 40 percent who took the drug had complete or near-complete hair regrowth after 36 weeks. After a year, nearly half of the patients had their hair back.

Dr. Brett King, a dermatology professor at Yale University, was the principal investigator for the two Lilly trials and is also leading trials sponsored by the other companies. He said he was optimistic that the success rate for the drugs would get better. Manufacturers may be able to improve the JAK inhibitors for alopecia areata. And when all three companies have drugs on the market, patients who do not respond to one company’s drug might respond to one of the others.

Patients in the Lilly study experienced relatively mild side effects, including a small increased risk of acne, urinary tract infections and other infections. Those side effects were easily treatable or improved without treatment.

The Lilly trial results “are impressive,” wrote Dr. Andrew Messenger of the University of Sheffield and Matthew Harries of the University of Manchester in an accompanying editorial. They added that the findings “represent the first published phase 3 trials of any treatment for this condition.”

More than 300,000 Americans live with severe alopecia areata, according to the F.D.A. The impact of the disease is hard to overstate, Dr. King said.

For most people with alopecia areata, the disease manifests as one or a few small bald patches on the head. But those with severe cases have something much worse. They may notice small bald spots on their heads one day. Three months or even three weeks later, they have no hair on their bodies.

Dr. King is widely credited by colleagues for piquing interest in the use of JAK inhibitors to treat alopecia areata. He said it all began when he noticed three abstracts presented at medical meetings in 2012 and 2013. The studies, led by Dr. Raphael Clynes and Dr. Angela Christiano of Columbia University, involved mice but indicated that JAK inhibitors might reverse alopecia areata.

Shortly afterward, a 25-year-old man named Kyle came to see Dr. King for the treatment of psoriasis. He had almost no hair and his head and body had big, red scaly psoriasis plaques.

“I looked at him and said, ‘You have alopecia areata,’” Dr. King said.

Kyle began noticing he had severe hair loss when he was at a dance in high school, wearing a hat. He went to the bathroom, took off his hat and, to his horror, found a large amount of hair in the hat.

“It’s a Twilight Zone episode,” Dr. King said.

He looked at Kyle and said, “If you want to try something wild that has not been done before, there is a medicine approved for rheumatoid arthritis and being developed for psoriasis. There is some suggestion in mice that it might work.”

Kyle agreed to take tofacitinib, a JAK inhibitor made by Pfizer that is similar to the Lilly drug. Eight months later, he had his hair back.

After Dr. King published a report on Kyle, other dermatologists began trying JAK inhibitors.

Dr. Maryanne Makredes Senna, the director of the Hair Loss Center of Excellence at Beth Israel Lahey Health in Massachusetts, was among them.

She would prevail upon insurers to cover the drugs, and sometimes she would succeed.

“It’s a beautiful thing to see the amazing impact,” said Dr. Senna, who has received consulting fees from Eli Lilly and Pfizer. “They come in with no hair, totally withdrawing from life. Their eyes are cast down. They come back and say, ‘I have my life back. I have my self back.’”

Dr. Natasha Atanaskova Mesinkovska, the chief scientific officer at the National Alopecia Areata Foundation and a dermatology professor at the University of California, Irvine, helped the pharmaceutical companies find patients for their trials. She, too, has been impressed by the results in those who have responded to the drugs.

Severe hair loss not only “robs a person of their identity” but is “a medical issue,” she said, adding that when people lose hair in their nose and ears, it affects allergies and hearing.

Christian Daniels, 27, a data center technician who lives in Peoria, Ill., said hair loss also affected his eyes. Without eyelashes, dust would get into his eyes and irritate them so much he began putting Vaseline on his eyelids.

Mr. Daniels’s hair started falling out when he was 25. Within a month, all of his body hair was gone.

Covid-19 was “a blessing in disguise,” he said, because he could work at home.

“I felt like my life had been put on hold,” he said. “I felt like the only thing that mattered was how to get my hair back.”

He found the Lilly trials by “Googling and Googling.”

Now, he said, “it’s almost like it never happened,” although he still has flashbacks sometimes when he looks in a mirror and remembers his hairless self.

Dr. Brittany Craiglow, a dermatologist in private practice in Fairfield, Conn., who is married to Dr. King, said severe alopecia areata was especially difficult for children.

One patient, Cassidy Mackwell of Canton, Mass., lost her hair when she was 8. When adults saw her, they assumed she had cancer.

“People would come up to Cassidy when we were in a restaurant having dinner,” said her mother, Melissa Mackwell. Some would even try to pay for their meals. “They would hug her and say, ‘I’m so sorry. Keep fighting.’”

One of Dr. Craiglow’s patients, Brooke Nelson, who lives in Belleville, N.J., lost all of her long blond hair when she was in first grade. Brooke was so embarrassed by her hair loss that her mother, Danielle Nelson, home-schooled her.

She took Brooke to medical center after medical center, to doctor after doctor, but to no avail. “I would have given up my house, given up everything if that meant giving Brooke back her hair,” Ms. Nelson said.

Ms. Nelson was ready to take Brooke to China for stem cell therapy when she found Dr. Craiglow, who gave Brooke a JAK inhibitor. Her hair grew back.

“It was a miracle,” Ms. Nelson said.

Click here to read the full New York Times article.